{"nctId":"NCT01337167","briefTitle":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","startDateStruct":{"date":"2011-04-19","type":"ACTUAL"},"conditions":["Bacterial Infections","Virus Diseases"],"count":1473,"armGroups":[{"label":"V419","type":"EXPERIMENTAL","interventionNames":["Biological: V419","Biological: DAPTACEL™","Biological: PedvaxHIB™","Biological: Prevnar 13™","Biological: RotaTeq™"]},{"label":"Control","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: DAPTACEL™","Biological: Prevnar 13™","Biological: RotaTeq™","Biological: PENTACEL™","Biological: Recombivax HB vaccine","Biological: ActHIB™"]}],"interventions":[{"name":"V419","otherNames":[]},{"name":"DAPTACEL™","otherNames":[]},{"name":"PedvaxHIB™","otherNames":[]},{"name":"Prevnar 13™","otherNames":[]},{"name":"RotaTeq™","otherNames":["V260"]},{"name":"PENTACEL™","otherNames":[]},{"name":"Recombivax HB vaccine","otherNames":[]},{"name":"ActHIB™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria :\n\n* Participant is a healthy infant\n* Participant has received one dose of monovalent hepatitis B vaccine prior to or at 1 month of age\n\nExclusion Criteria :\n\n* Participant has received more than one dose of monovalent hepatitis B vaccine or hepatitis B based combination vaccine prior to study entry\n* Participant has been vaccinated with any acellular pertussis or whole cell pertussis based combination vaccines, haemophilus influenzae type b conjugate, poliovirus, pneumococcal conjugate or pneumococcal polysaccharide, rotavirus, or any combination of the above\n* Participant has had a fever ≥38.0°C (≥110.4°F) within 24 hours of study enrollment\n* Participant was vaccinated with any non-study vaccine (i.e., inactivated, conjugated, live virus vaccine) within 30 days prior to study enrollment, except for inactivated influenza vaccine which will be permitted 15 days or more prior to enrollment\n* Participant has hepatitis B surface antigen (HBsAg) seropositivity (by medical history)\n* Participant has a history of haemophilus influenzae type B, hepatitis B, diphtheria, tetanus, pertussis, poliomyelitis, rotavirus, or pneumococcal infection","healthyVolunteers":true,"sex":"ALL","minimumAge":"46 Days","maximumAge":"89 Days","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen","description":"Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate. Response was evaluated for titer \\>=0.15 μg/mL and \\>=1.0 μg/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.97","spread":null},{"groupId":"OG001","value":"75.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.25","spread":null},{"groupId":"OG001","value":"92.41","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Hepatitis B Surface Antigen","description":"Participant serum samples were collected for testing with an enhanced chemiluminescence assay for antibodies to Hepatitis B Surface Antigen. Response was defined as a titer \\>=10 milli International units (mIU)/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.42","spread":null},{"groupId":"OG001","value":"98.58","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Diphtheria Toxin","description":"Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to diphtheria toxin. Response was defined as a titer \\>=0.1 International unit (IU)/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.44","spread":null},{"groupId":"OG001","value":"86.26","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Tetanus Toxin","description":"Participant serum samples were collected for testing with an ELISA for anti-tetanus antibodies. Response was defined as a titer \\>=0.1 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.87","spread":null},{"groupId":"OG001","value":"99.49","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Pertussis Toxin","description":"Participant serum samples were collected for testing with an Enzyme-linked Immunosorbent Assay (ELISA) for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was \\<4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was \\>=4X LLOQ; 2) if the predose titer was \\>=4X LLOQ then the postdose titer was \\>= the predose titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.12","spread":null},{"groupId":"OG001","value":"98.47","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was \\<4X LLOQ then the postdose titer was \\>=4X LLOQ; 2) if the predose titer was \\>=4X LLOQ then the postdose titer was \\>= the predose titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.31","spread":null},{"groupId":"OG001","value":"92.07","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Pertussis Pertactin","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was \\<4X LLOQ then the postdose titer was \\>=4X LLOQ; 2) if the predose titer was \\>=4X LLOQ then the postdose titer was \\>= the predose titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.35","spread":null},{"groupId":"OG001","value":"82.05","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Pertussis Fimbriae","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was \\<4X LLOQ then the postdose titer was \\>=4X LLOQ; 2) if the predose titer was \\>=4X LLOQ then the postdose titer was \\>= the predose titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.20","spread":null},{"groupId":"OG001","value":"86.19","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Poliovirus Type 1","description":"Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 1. Response is defined as a titer \\>=8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.00","spread":null},{"groupId":"OG001","value":"98.24","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Poliovirus Type 2","description":"Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 2. Response is defined as a titer \\>=8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.00","spread":null},{"groupId":"OG001","value":"99.75","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Poliovirus Type 3","description":"Participant serum samples were collected for testing with a Micrometabolic Inhibition Test for neutralizing antibodies to Poliovirus Type 3. Response is defined as a titer \\>=8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.00","spread":null},{"groupId":"OG001","value":"99.75","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration of Antibodies to Pertussis Toxin","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. The unit of measure is ELISA units/mL (EU/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110.40","spread":null},{"groupId":"OG001","value":"86.54","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.17","spread":null},{"groupId":"OG001","value":"74.44","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration of Antibodies to Pertussis Pertactin","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.22","spread":null},{"groupId":"OG001","value":"66.16","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration of Antibodies to Pertussis Fimbriae","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"235.62","spread":null},{"groupId":"OG001","value":"185.54","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Pertussis Toxin","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin. Response was defined as follows: 1) if the predose titer was \\<4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was \\>=4X LLOQ; 2) if the predose titer was \\>=4X LLOQ then the postdose titer was \\>= the predose titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.29","spread":null},{"groupId":"OG001","value":"97.42","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Pertussis Filamentous Hemagglutinin","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin. Response was defined as follows: 1) if the predose titer was \\<4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was \\>=4X LLOQ; 2) if the predose titer was \\>=4X LLOQ then the postdose titer was \\>= the predose titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.42","spread":null},{"groupId":"OG001","value":"93.14","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Pertussis Pertactin","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin. Response was defined as follows: 1) if the predose titer was \\<4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was \\>=4X LLOQ; 2) if the predose titer was \\>=4X LLOQ then the postdose titer was \\>= the predose titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.01","spread":null},{"groupId":"OG001","value":"93.45","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Responding to Pertussis Fimbriae","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae. Response was defined as follows: 1) if the predose titer was \\<4 times the lower limit of quantitation (4X LLOQ) then the postdose titer was \\>=4X LLOQ; 2) if the predose titer was \\>=4X LLOQ then the postdose titer was \\>= the predose titer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.29","spread":null},{"groupId":"OG001","value":"91.17","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration of Antibodies to Pertussis Toxin","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis toxin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127.22","spread":null},{"groupId":"OG001","value":"91.31","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration of Antibodies to Pertussis Filamentous Hemagglutinin","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis filamentous hemagglutinin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.92","spread":null},{"groupId":"OG001","value":"89.18","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration of Antibodies to Pertussis Pertactin","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis pertactin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108.05","spread":null},{"groupId":"OG001","value":"139.35","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration of Antibodies to Pertussis Fimbriae","description":"Participant serum samples were collected for testing with an ELISA for antibodies to pertussis fimbriae.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"658.50","spread":null},{"groupId":"OG001","value":"414.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration of Antibodies to Polyribosylribitol Phosphate Antigen","description":"Participant serum samples were collected for testing with a radioimmunoassay for antibodies to Haemophilus influenza type b capsular polysaccharide polyribosylribitol phosphate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.11","spread":null},{"groupId":"OG001","value":"3.18","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration of Immunoglobulin A (IgA) Antibodies to Rotavirus","description":"Participant serum samples were collected for testing with an Enzyme-linked Immunosorbent assay for IgA antibodies to rotavirus.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"278.19","spread":null},{"groupId":"OG001","value":"274.46","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Solicited Injection-site or Systemic Reactions","description":"Solicited injection-site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Pyrexia, Vomiting, Crying abnormal, Somnolence, Decreased appetite, and Irritability. Grade 3 Solicited injection site reaction: Pain, Cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling, \\>5 cm. Grade 3 Solicited systemic reactions: Pyrexia, \\>=39.5°C (\\>=103.1°F) rectal; Vomiting, \\>=6 episodes per 24 hours or requiring parenteral hydration; Crying abnormal, \\>3 hours; Somnolence, Sleeping most of the time or difficult to wake up; Decreased appetite, Refuses \\>=3 feeds or refuses most feeds; Irritability, Inconsolable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.4","spread":null},{"groupId":"OG001","value":"71.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.8","spread":null},{"groupId":"OG001","value":"42.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.1","spread":null},{"groupId":"OG001","value":"34.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.4","spread":null},{"groupId":"OG001","value":"34.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","spread":null},{"groupId":"OG001","value":"21.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":null},{"groupId":"OG001","value":"72.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.1","spread":null},{"groupId":"OG001","value":"71.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","spread":null},{"groupId":"OG001","value":"43.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.1","spread":null},{"groupId":"OG001","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting One or More Solicited Adverse Events Related to Study Drug","description":"Solicited systemic adverse events: pyrexia, vomiting, crying abnormal, somnolence, decreased appetite, and irritability. Adverse events deemed related to study drug were those judged to be definitely related, probably related, or possibly related by the investigator.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.1","spread":null},{"groupId":"OG001","value":"32.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"16.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null},{"groupId":"OG001","value":"68.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.7","spread":null},{"groupId":"OG001","value":"40.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":null},{"groupId":"OG001","value":"77.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting One or More Solicited Adverse Events Related to Study Drug","description":"Solicited systemic adverse events: pyrexia, vomiting, crying abnormal, somnolence, decreased appetite, and irritability. Adverse events deemed related to study drug were those judged to be definitely related, probably related, or possibly related by the investigator.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":null},{"groupId":"OG001","value":"12.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":null},{"groupId":"OG001","value":"16.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":null},{"groupId":"OG001","value":"16.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"7.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":null},{"groupId":"OG001","value":"8.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9","spread":null},{"groupId":"OG001","value":"48.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4","spread":null},{"groupId":"OG001","value":"42.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","spread":null},{"groupId":"OG001","value":"36.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.6","spread":null},{"groupId":"OG001","value":"54.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"41.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.3","spread":null},{"groupId":"OG001","value":"35.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.4","spread":null},{"groupId":"OG001","value":"24.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","spread":null},{"groupId":"OG001","value":"19.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.9","spread":null},{"groupId":"OG001","value":"17.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":null},{"groupId":"OG001","value":"60.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.6","spread":null},{"groupId":"OG001","value":"52.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.7","spread":null},{"groupId":"OG001","value":"48.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Elevated Temperature by Severity","description":"Maximum temperature (all routes) was based on actual temperatures recorded with no adjustments to the measurement route. Maximum temperature (rectal) was required of all participants if the reading by another method was \\>=38.0°C.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"64.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":null},{"groupId":"OG001","value":"19.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":null},{"groupId":"OG001","value":"15.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.5","spread":null},{"groupId":"OG001","value":"57.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","spread":null},{"groupId":"OG001","value":"17.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":null},{"groupId":"OG001","value":"14.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pyrexia, Febrile Convulsion, or Convulsion","description":"The percentage of participants with one or more adverse events (AE), serious adverse events (SAE), and vaccine-related SAE (pyrexia, febrile convulsion, and convulsion) is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":null},{"groupId":"OG001","value":"35.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pyrexia, Febrile Convulsion, or Convulsion","description":"The percentage of participants with one or more adverse events (AE), serious adverse events (SAE), and vaccine-related SAE (pyrexia, febrile convulsion, and convulsion) is reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":58,"n":980},"commonTop":["Irritability","Injection-site pain","Crying","Somnolence","Injection-site erythema"]}}}